Literature DB >> 6454383

Pharmacokinetics of moxalactam in patients with renal insufficiency.

M Lam, C V Manion, A W Czerwinski.   

Abstract

Moxalactam pharmacokinetics were determined in 18 patients with renal insufficiency (creatinine clearance, 0 to 99 ml/min). Each patient was given 0.5 g of moxalactam intramuscularly. Drug half-life ranged from 4.1 to 49.1 h and correlated inversely with creatinine clearance (r = -0.97). Total body drug clearance ranged from 0 to 88 ml/min, and renal clearance ranged from 0 to 57 ml/min. In four patients studied during hemodialysis, drug half-life was 21.7 +/- 7.5 h (mean +/- standard error) between dialyses and 4.4 +/- 0.5 h during dialysis. Moxalactam dialysance averaged 44 +/- 2 ml/min per m2 of dialyzer surface area, and approximately 50% of the drug was removed during a single hemodialysis. We confirmed that moxalactam is eliminated from the body primarily by renal excretion. Recommendations are given for dosage adjustment in patients with renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6454383      PMCID: PMC181454          DOI: 10.1128/AAC.19.3.461

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

Review 1.  Clinical pharmacokinetics (second of two parts).

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1975-11-06       Impact factor: 91.245

2.  COMPT, a time-sharing program for nonlinear regression analysis of compartmental models of drug distribution.

Authors:  M Pfeffer
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

3.  Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers.

Authors:  J N Parsons; J M Romano; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

4.  ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates.

Authors:  R D Brown; J E Manno
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

5.  Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.

Authors:  W H Hall; B J Opfer; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

  5 in total
  13 in total

1.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

2.  Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.

Authors:  S Srinivasan; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

4.  Pharmacokinetics of moxalactam in elderly subjects.

Authors:  M H Andritz; R P Smith; A L Baltch; P E Griffin; J V Conroy; N Sutphen; M C Hammer
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

5.  Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vincon; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  High performance liquid chromatographic determination of moxalactam in human plasma and cerebrospinal fluid.

Authors:  J Nielsen; G Karlaganis; H M von Hattingberg; U B Schaad
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Steady-state moxalactam pharmacokinetics in patients: noncompartmental versus two-compartmental analysis.

Authors:  D J Swanson; D P Reitberg; I L Smith; P B Wels; J J Schentag
Journal:  J Pharmacokinet Biopharm       Date:  1983-08

8.  Pharmacokinetics of cefotiam in patients with impaired renal function and in those undergoing hemodialysis.

Authors:  K Konishi; Y Ozawa
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 10.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.